See more : Costco Wholesale Corporation (COST) Income Statement Analysis – Financial Results
Complete financial analysis of SAB Biotherapeutics, Inc. (SABS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SAB Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Falcon Oil & Gas Ltd. (FO.V) Income Statement Analysis – Financial Results
- Shoper S.A. (SHO.WA) Income Statement Analysis – Financial Results
- BHP Group Limited (BHPLF) Income Statement Analysis – Financial Results
- Monarch Networth Capital Limited (MONARCH.BO) Income Statement Analysis – Financial Results
- DevEx Resources Limited (DEV.AX) Income Statement Analysis – Financial Results
SAB Biotherapeutics, Inc. (SABS)
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.24M | 23.90M | 60.88M | 55.24M | 3.44M |
| Cost of Revenue | 3.75M | 3.29M | 1.65M | 0.00 | 0.00 |
| Gross Profit | -1.51M | 20.61M | 59.22M | 55.24M | 3.44M |
| Gross Profit Ratio | -67.28% | 86.23% | 97.28% | 100.00% | 100.00% |
| Research & Development | 16.52M | 36.44M | 57.18M | 27.91M | 8.02M |
| General & Administrative | 23.80M | 16.38M | 17.09M | 6.77M | 4.10M |
| Selling & Marketing | -3.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.05M | 16.38M | 17.09M | 6.77M | 4.10M |
| Other Expenses | 0.00 | -23.90M | -60.88M | 4.00K | 2.59K |
| Operating Expenses | 40.31M | 28.92M | 13.39M | 34.68M | 12.12M |
| Cost & Expenses | 40.31M | 28.92M | 13.39M | 34.68M | 12.12M |
| Interest Income | 584.97K | 71.07K | 23.12K | 26.13K | 113.13K |
| Interest Expense | 315.28K | 301.58K | 294.46K | 469.15K | 428.48K |
| Depreciation & Amortization | 3.75M | 3.29M | 1.65M | 548.18K | 323.41K |
| EBITDA | -38.08M | -15.12M | -15.20M | 21.14M | -8.23M |
| EBITDA Ratio | -1,700.56% | -113.62% | -19.24% | 38.26% | -239.25% |
| Operating Income | -38.08M | -28.92M | -13.39M | 20.56M | -8.67M |
| Operating Income Ratio | -1,700.56% | -120.97% | -22.00% | 37.22% | -252.01% |
| Total Other Income/Expenses | -4.12M | 10.20M | -3.75M | -439.02K | -312.75K |
| Income Before Tax | -42.19M | -18.72M | -17.14M | 20.12M | -8.99M |
| Income Before Tax Ratio | -1,884.50% | -78.29% | -28.16% | 36.42% | -261.09% |
| Income Tax Expense | 0.00 | 25.63K | 299.95K | 473.15K | 431.07K |
| Net Income | -42.19M | -18.74M | -17.44M | 20.12M | -9.42M |
| Net Income Ratio | -1,884.50% | -78.40% | -28.66% | 36.42% | -273.62% |
| EPS | -7.64 | -4.31 | -6.38 | 7.92 | -0.22 |
| EPS Diluted | -7.64 | -4.31 | -6.38 | 7.45 | -0.22 |
| Weighted Avg Shares Out | 5.52M | 4.35M | 2.73M | 2.54M | 43.47M |
| Weighted Avg Shares Out (Dil) | 5.52M | 4.35M | 2.73M | 2.70M | 43.47M |
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB Biotherap
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
SAb Biotherapeutics Rebrands as SAB BIO
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
SAB Biotherapeutics Announces Departure of Chief Financial Officer
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
Source: https://incomestatements.info
Category: Stock Reports